Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan

• Published in: BMC infectious diseases Vol. 19; no. 1; p. 116
• Main Authors: Khan, Muhammad Tahir, Malik, Shaukat Iqbal, Ali, Sajid, Masood, Nayyer, Nadeem, Tariq, Khan, Anwar Sheed, Afzal, Muhammad Tanvir
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.02.2019; BioMed Central; BMC
• Subjects: Control; Dosage and administration; Drug resistance; Drug therapy; Gene mutation; Genes; Genetic aspects; Infectious diseases; Investigations; Methods; Microbial drug resistance; Multidrug resistant organisms; Mutation; Mutations; Mycobacterium tuberculosis; pncA; PncA gene; Population; Pyrazinamide; Resistance; Sensitivity; Subpopulations; Tuberculosis; Pakistan; China; Resistance; pncA; Mutations; Pyrazinamide

Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB). The prodrug (PZA) is converted to its active form, pyrazinoic acid (POA) by MTB pncA-encoded pyrazinamidase (PZase). Mutation...